Home/News Feed/Moderna leads with growing sales and promising cancer vaccine; BioNTech faces leadership changes and slower progress. Moderna and BioNTech, once known for their COVID-19 vaccines, are shifting focus to cancer treatments. Moderna's stock has risen due to its personalized cancer vaccine showing strong trial results and growing revenue from multiple approved products, including a new flu vaccine. BioNTech, despite a strong cash position and multiple cancer trials, faces leadership changes and mixed trial outcomes, with its COVID vaccine still its only commercial product. Investors see Moderna as the better long-term buy due to current sales growth and near-term cancer therapy prospects, while BioNTech's biggest opportunities lie further in the future amid management transitions.
As investors weigh the future of cancer therapies, Moderna and BioNTech show distinct market signals on Pluang. As of Nov 20, 2026 16:01 WIB, Moderna trades at USD 197.68 with a market cap of $79.63B but sees heavy selling activity at 96% sell orders. BioNTech, priced at USD 80.59 with a $20.64B market cap, has a more balanced order flow with 53% buy orders. Typical hold times are similar, around two months, reflecting cautious but engaged investor interest.